Navigation Links
GeneNews announces management changes to support commercialization of ColonSentry(TM)
Date:6/2/2008

TORONTO, June 2 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced management changes to support the commercialization of the Company's first product, ColonSentry(TM).

Effective May 31, 2008, Dr. K. Wayne Marshall has resigned as President and CEO to take on new duties as Chief Clinical Scientist for GeneNews. Dr. Marshall has also been appointed Vice Chair of the GeneNews Board of Directors. The Board has appointed a committee of three independent directors to manage the search for a new President and CEO. In the interim, Dr. Heiner Dreismann, an independent director of GeneNews and former President and CEO of Roche Molecular Diagnostics, will oversee the Company's business as Lead Director. Ms. Gailina Liew, formerly Senior Vice President, has also been appointed as acting Chief Operating Officer with responsibility for the operations of the Company.

"As GeneNews transitions into a commercial enterprise and prepares for the launch of ColonSentry, Wayne, the Board and I were in accordance that the timing was appropriate to transition leadership of the Company to a President and CEO with experience in the global commercialization of molecular diagnostics," said Mr. Rory Riggs, Chair of the Board of Directors. "In the interim, Dr. Dreismann's extensive experience and leadership at Roche Molecular Diagnostics will ensure that GeneNews is well prepared to enter the commercialization phase."

"We have worked hard to ensure that ColonSentry is the world's first blood-based test for colorectal cancer screening. I'm excited about the upcoming commercial launch of ColonSentry and committed to contributing to the future success of GeneNews in my new role as Chief Clinical Scientist and Vice Chair of the Board," added Dr. Marshall.

"I welcome the opportunity to play a leading role during this transition from development to commercialization," said Dr. Dreismann. "GeneNews has developed important technology that is expected to positively impact the molecular diagnostic field."

About GeneNews

--------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit http://www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. GeneNews announces 2007 year end results
7. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
8. GeneNews Announces First Quarter Results
9. Genenews adds two members to its Board of Directors
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... R&D program for the development of future natural products for ... research and development center in Israel ... Stockton has a variety of products adapted ... active in more than 35 counties worldwide. ... flagship product Timorex Gold ® is used to control ...
(Date:2/5/2016)... 2016 ATCC, the premier global biological materials ... medical and life science researchers that are working to ... CDC website . --> ... is a single-stranded RNA virus of the Flaviviridae family, ... and Chikungunya Viruses. Zika virus is transmitted to humans ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf Media Inc ., ... interactive FDA compliance training course, Writing Effective SOPs (Standard ... interactive course on Morf Playbook—now conveniently available on smartphones and PCs--provides step by ...
(Date:2/4/2016)... 2016 Beike Biotechnology, the Shenzhen ... a ceremony in late 2015 to mark their successful ... 2016. --> --> ... Personalized Cell Therapy" was hosted by the Shenzhen Cell ... subsidiaries of Beike Biotechnology Co., Ltd. ...
Breaking Biology Technology:
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ) ... "Global Facial Recognition Market 2016-2020" report ... ) has announced the addition of the ... report to their offering. --> ... announced the addition of the "Global ...
(Date:2/3/2016)... Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases with ... Vigilant Solutions. Brian Wenberg explains, "I ... was walking out of a convenience store and witnessed an elderly male back ... striking his vehicle and leaving the scene.  In his ...
(Date:2/2/2016)... Checkpoint Inhibitors for Cancer – Explore ... you interested in the future of cancer drugs? ... Visiongain,s report gives those predictions to 2026 at ... Avoid falling behind in data or losing ... those emerging cancer therapies can achieve. There you ...
Breaking Biology News(10 mins):